Xavier Forns

Grupo de investigación

Enfermedades hepáticas víricas, genéticas e inmuno-mediadas Eminent researcher

xforns@clinic.cat 0000-0002-8188-1764

Publicaciones destacadas

Incidence and Clinical Significance of Recompensation After HCV Cure

Autores:
Semmler, Georg; Lens, Sabela; Hidalgo, Alvaro; Lopez, Sonia Alonso; Perez-Perez, Maria;

(...)

Genesca, Joan; Banares, Rafael; Forns, Xavier; Fernandez, Inmaculada; Mandorfer, Mattias.

Referencia: Clinical Gastroenterology and Hepatology 2025.
Exchangeable copper for patients with Wilson disease at follow-up: Rethinking normal ranges or changing methodology

Autores:
Marino, Zoe; Garcia-Sola, Claudia; Rios, Jose; Bono, Ariadna; Garcia, Sonia;

(...)

Andreu, Rocio; Aguado, Cristina; Forns, Xavier; Torra, Merce; Berenguer, Marina.

Referencia: HEPATOLOGY 2025.
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta

Autores:
Degasperi, Elisabetta; Scholtes, Caroline; Testoni, Barbara; Renteria, Sara Uceda; Anolli, Maria Paola;

(...)

Perez-del-Pulgar, Sofia; Heil, Marintha; Levrero, Massimo; Zoulim, Fabien; Lampertico, Pietro.

Referencia: JOURNAL OF HEPATOLOGY 2025.
Predictors of hepatic flares after nucleos(t)ide analogue cessation - Results of a global cohort study (RETRACT-B study)

Autores:
Dongelmans, Edo J; Hirode, Grishma; Hansen, Bettina E; Chen, Chien-Hung; Su, Tung-Hung;

(...)

Kao, Jia-Horng; Cornberg, Markus; Sonneveld, Milan J; Jeng, Wen-Juei; Janssen, Harry L A.

Referencia: JOURNAL OF HEPATOLOGY 2025.
EASL position paper on clinical follow-up after HCV cure

Autores:
Reiberger, Thomas; Lens, Sabela; Cabibbo, Giuseppe; Nahon, Pierre; Zignego, Anna Linda;

Deterding, Katja; Elsharkawy, Ahmed M; Forns, Xavier.

Referencia: JOURNAL OF HEPATOLOGY 2024.
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

Autores:
Ruiz-Cobo, Juan Carlos; Llaneras, Jordi; Forns, Xavier; Gallego Moya, Adolfo; Conde Amiel, Isabel;

(...)

Bernal-Monterde, Vanesa; Delgado, Manuel; Turnes, Juan; Lens, Sabela; Buti, Maria.

Referencia: ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2024.
Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure

Autores:
Semmler, Georg; Lopez, Sonia Alonso; Pons, Monica; Lens, Sabela; Dajti, Elton;

(...)

Reiberger, Thomas; Forns, Xavier; Genesca, Joan; Banares, Rafael; Mandorfer, Mattias.

Referencia: JOURNAL OF HEPATOLOGY 2024.
Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study)

Autores:
Hirode, Grishma; Choi, Hannah S J; Chen, Chien-Hung; Su, Tung-Hung; Seto, Wai-Kay;

(...)

Kao, Jia-Horng; Cornberg, Markus; Hansen, Bettina E; Jeng, Wen-Juei; Janssen, Harry L A.

Referencia: GASTROENTEROLOGY 2022.
Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future

Autores:
Rodriguez-Tajes, Sergio; Pocurull, Anna; Castillo, Joaquin; Casanova, Gherzon; Vega, Laia;

(...)

Marino, Zoe; Londono, Maria-Carlota; Forner, Alejandro; Torres, Ferran; Forns, Xavier.

Referencia: JOURNAL OF HEPATOLOGY 2020.

Proyectos destacados

Análisis transcriptómico espacial de las interacciones virus-huésped y la respuesta al tratamiento en la hepatitis crónica Delta (SPACE-D)

Investigador/a principal: Sabela Lens García, Xavier Forns Bernhardt

Financiador: Instituto de Salud Carlos III (ISCIII)

Código: PI25/01234

Duración: 01/01/2026 - 31/12/2028
Exploring the mechanisms used by HBV to evade the host immune defenses

Investigador/a principal: Xavier Forns Bernhardt, XAvier Forns Sofia Pérez del Pulgar Thais Leonel Anna Pocurull Mala K. Maini Sergio Rodrígues-Tajes Ester Garcia Pras Ernest Belmonte, Sofia Pérez del Pulgar Xavier Forns

Financiador: ISCIII

Código: PI22/00013

Duración: 01/01/2023 - 31/12/2025
TherVacB: A therapeutic vaccine to cure hepatitis B

Investigador/a principal: Xavier Forns Bernhardt

Financiador: European Commission

Código: 848223

Duración: 01/01/2020 - 31/12/2024

Web: https://www.thervacb.eu/

Xavier Forns

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

Análisis transcriptómico espacial de las interacciones virus-huésped y la respuesta al tratamiento en la hepatitis crónica Delta (SPACE-D)

Exploring the mechanisms used by HBV to evade the host immune defenses

TherVacB: A therapeutic vaccine to cure hepatitis B

Suscríbete a la Newsletter del Clínic